Can the development of schizophrenia be prevented?
Date and time: 27 Mar 2022 from 09:00 to 10:00Location: Virtual
Presented by: Prof. Dr. Christoph U. Correll, MD
Abstract:
Due to the severity and chronicity of schizophrenia and data indicating that the duration of untreated psychosis is detrimental for illness outcomes, prevention of psychosis during the clinical high-risk state and early recognition and intervention as soon after the first episode has occurred are of vital importance. However, the value of early intervention in psychosis and allocation of public resources has long been debated because outcomes in people with schizophrenia spectrum disorders have remained suboptimal. This presentation will review the clinical high-risk for psychosis research data that have accrued over the past 20 years and summarize the current knowledge and state of the field.
Learning Objectives:
Objective #1 Describe risk factors for the development of schizophrenia
Objective #2 Recognize criteria for the attenuated psychosis syndrome and its outcomes
Objective #3 Review potential interventions for individuals at high-risk for psychosis
Literature References
Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, Galderisi S, Bechdolf A, Pfennig A, Kessing LV, van Amelsvoort T, Nieman DH, Domschke K, Krebs MO, Koutsouleris N, McGuire P, Do KQ, Arango C. Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. JAMA Psychiatry. 2020 Jul 1;77(7):755-765.
Mei C, van der Gaag M, Nelson B, Smit F, Yuen HP, Berger M, Krcmar M, French P, Amminger GP, Bechdolf A, Cuijpers P, Yung AR, McGorry PD. Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis. Clin Psychol Rev. 2021 Jun;86:102005.
Disclosure of Conflict of Interest
- Do you have a relationship with a for-profit and/or a not-forprofit organization to disclose?
Yes
- All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity.
Dr. Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Cardio Diagnostics, Compass, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Pharmabrain, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris.
- Patents on a drug, product or device
None
- Funded grants or clinical trials
Janssen, Takeda
- Membership on advisory boards or speakers' bureaus
AbbVie, Acadia, Alkermes, Allergan, Angelini, Axsome, Compass, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mylan, Neurocrine, Noven, Otsuka, Recordati, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris.
- Any direct financial payments including receipt of honoraria
AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Cardio Diagnostics, Compass, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Pharmabrain, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris.
- I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.
Yes
- I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).Note: You must declare all off-label use to the audience during your presentation
Yes
- By clicking "I agree", you are acknowledging that the information provided is accurate and that you understand that this information will be publicly available.
I agree